Journal article

Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections.

Luis E Jauregui, Simon Babazadeh, Elyse Seltzer, Lisa Goldberg, Dainis Krievins, Mark Frederick, David Krause, Igors Satilovs, Zilvinas Endzinas, Jeffrey Breaux, William O'Riordan

Clin Infect Dis | Oxford University Press (OUP) | Published : 2005

Abstract

BACKGROUND: Dalbavancin, a novel lipoglycopeptide with a pharmacokinetic profile that allows weekly dosing, is active against gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA). The efficacy of dalbavancin for treatment of skin and skin structure infections (SSSIs) was demonstrated in a phase 2 study. METHODS: In a phase 3 noninferiority study, patients with complicated SSSIs, including infections known or suspected to involve MRSA, were randomized (ratio, 2 : 1) in a double-blind manner to receive dalbavancin (1000 mg given intravenously on day 1 and 500 mg given intravenously on day 8) or linezolid (600 mg given intravenously or intravenously/orally every ..

View full abstract